Characterization of the structural modifications accompanying the loss of HBsAg particle immunogenicity

Vaccine

Volumn 32, Issue 9, 2014, Pages 1049-1054

  Greiner, Vanille J ^a   Manin, Catherine ^b   Larquet, Eric ^c   Ikhelef, Nabila ^b   Gréco, Frédéric ^b   Naville, Sophie ^b   Milhiet, Pierre Emmanuel ^d   Ronzon, Frédéric ^b   Klymchenko, Andrey ^a   Mély, Yves ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b SANOFI PASTEUR   (France)

^c LABORATOIRE D ENZYMOLOGIE ET BIOCHIMIE STRUCTURALES   (France)

^d UNIV MONTPELLIER   (France)

Author keywords

Atomic force microscopy; Electron microscopy; Fluorescence spectroscopy; Fourier transform infrared spectroscopy; Hepatitis B surface antigen; Immunogenicity

Indexed keywords

ATOMIC FORCE MICROSCOPY; ELECTRON MICROSCOPY; FLUORESCENCE SPECTROSCOPY; FOURIER TRANSFORM INFRARED SPECTROSCOPY; HEPATITIS B SURFACE ANTIGEN; IMMUNOGENICITY;

ANIMALS; CIRCULAR DICHROISM; EPITOPES; FEMALE; HEPATITIS B SURFACE ANTIGENS; HOT TEMPERATURE; MICE; MICE, INBRED BALB C; MICROSCOPY, ATOMIC FORCE; MICROSCOPY, ELECTRON; PROTEIN STRUCTURE, SECONDARY; SPECTROPHOTOMETRY, INFRARED;

EID: 84895062108     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.01.012     Document Type: Article

References (34)

1. Gomez-Gutierrez J., Rodriguez-Crespo I., Peterson D.L., Gavilanes F. Antigenicity of hepatitis B surface antigen proteins reconstituted with phospholipids. Biochim Biophys Acta 1995, 1233:205-212.
2. Diminsky D., Moav N., Gorecki M., Barenholz Y. Physical, chemical and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles. Vaccine 1999, 18:3-17.
3. Gilbert R.J., Beales L., Blond D., Simon M.N., Lin B.Y., Chisari F.V., et al. Hepatitis B small surface antigen particles are octahedral. PNAS 2005, 102:14783-14788.
4. Satoh O., Imai H., Yoneyama T., Miyamura T., Utsumi H., Inoue K., et al. Membrane structure of the hepatitis B virus surface antigen particle. J Biochem 2000, 127:543-550.
5. McAleer W.J., Buynak E.B., Maigetter R.Z., Wampler D.E., Miller W.J., Hilleman M.R. Human hepatitis B vaccine from recombinant yeast. Nature 1984, 307:178-180.
6. Diminsky D., Schirmbeck R., Reimann J., Barenholz Y. Comparison between hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (Hansenula polymorpha): composition, structure and immunogenicity. Vaccine 1997, 15:637-647.
7. Bayer M.E., Blumberg B.S., Werner B. Particles associated with Australia antigen in the sera of patients with leukaemia, Down's syndrome and hepatitis. Nature 1968, 218:1057-1059.
8. Dane D.S., Cameron C.H., Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet 1970, 1:695-698.
9. Bruss V., Ganem D. The role of envelope proteins in hepatitis B virus assembly. PNAS 1991, 88:1059-1063.
10. Gavilanes F., Gomez-Gutierrez J., Aracil M., Gonzalez-Ros J.M., Ferragut J.A., Guerrero E., et al. Hepatitis B surface antigen. Role of lipids in maintaining the structural and antigenic properties of protein components. Biochem J 1990, 265:857-864.
11. Gavilanes F., Gonzalez-Ros J.M., Peterson D.L. Structure of hepatitis B surface antigen. Characterization of the lipid components and their association with the viral proteins. J Biol Chem 1982, 257:7770-7777.
12. Milhiet P.E., Dosset P., Godefroy C., Le Grimellec C., Guigner J.M., Larquet E., et al. Nanoscale topography of hepatitis B antigen particles by atomic force microscopy. Biochimie 2010, 93:254-259.
13. Mulder A.M., Carragher B., Towne V., Meng Y., Wang Y., Dieter L., et al. Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccine. PLoS One 2012, 7:e33235.
14. Zhao Q., Wang Y., Freed D., Fu T.M., Gimenez J.A., Sitrin R.D., et al. Maturation of recombinant hepatitis B virus surface antigen particles. Hum Vaccin 2006, 2:174-180.
15. Le Duff Y., Blanchet M., Sureau C. The pre-S1 and antigenic loop infectivity determinants of the hepatitis B virus envelope proteins are functionally independent. J Virol 2009, 83:12443-12451.
16. Salisse J., Sureau C. A function essential to viral entry underlies the hepatitis B virus a determinant. J Virol 2009, 83:9321-9328.
17. Stirk H.J., Thornton J.M., Howard C.R. A topological model for hepatitis B surface antigen. Intervirology 1992, 33:148-158.
18. Greiner V.J., Egele C., Oncul S., Ronzon F., Manin C., Klymchenko A., et al. Characterization of the lipid and protein organization in HBsAg viral particles by steady-state and time-resolved fluorescence spectroscopy. Biochimie 2010, 92:994-1002.
19. Satoh O., Umeda M., Imai H., Tunoo H., Inoue K. Lipid composition of hepatitis B virus surface antigen particles and the particle-producing human hepatoma cell lines. J Lipid Res 1990, 31:1293-1300.
20. WHO Recommendations to assure the quality, safety and efficacy of recombinant Hepatitis B vaccines. Proposed Replacement of: TRS 786, Annex 2 and TRS 889, Annex 4. Adopted by WHO ECBS 2010, WHO.
21. Klymchenko A.S., Duportail G., Ozturk T., Pivovarenko V.G., Mely Y., Demchenko A.P. Novel two-band ratiometric fluorescence probes with different location and orientation in phospholipid membranes. Chem Biol 2002, 9:1199-1208.
22. Ozturk T., Klymchenko A.S., Capan A., Oncul S., Cikrikci S., Taskiran S., et al. New 3-hydroxyflavone derivatives for probing hydrophobic sites in microheterogeneous systems. Tetrahedron 2007, 63:10290-10299.
23. Shynkar V.V., Klymchenko A.S., Duportail G., Demchenko A.P., Mely Y. Two-color fluorescent probes for imaging the dipole potential of cell plasma membranes. Biochim Biophys Acta 2005, 1712:128-136.
24. European Pharmacopoeia Assay of Hepatitis B Vaccine (rDNA) 2010, European Pharmacopoeia. 7th ed.
25. Chen Y.C., Delbrook K., Dealwis C., Mimms L., Mushahwar I.K., Mandecki W. Discontinuous epitopes of hepatitis B surface antigen derived from a filamentous phage peptide library. PNAS 1996, 93:1997-2001.
26. Iwarson S., Tabor E., Thomas H.C., Goodall A., Waters J., Snoy P., et al. Neutralization of hepatitis B virus infectivity by a murine monoclonal antibody: an experimental study in the chimpanzee. J Med Virol 1985, 16:89-96.
27. Greiner V.J., Ronzon F., Larquet E., Desbat B., Esteves C., Bonvin J., et al. The structure of HBsAg particles is not modified upon their adsorption on aluminium hydroxide gel. Vaccine 2012, 30:5240-5245.
28. Godet J., Ramalanjaona N., Sharma K.K., Richert L., de Rocquigny H., Darlix J.L., et al. Specific implications of the HIV-1 nucleocapsid zinc fingers in the annealing of the primer binding site complementary sequences during the obligatory plus strand transfer. Nucleic Acids Res 2011, 39:6633-6645.
29. Zhao Q., Wang Y., Abraham D., Towne V., Kennedy R., Sitrin R.D. Real time monitoring of antigenicity development of HBsAg virus-like particles (VLPs) during heat- and redox-treatment. Biochem Biophys Res Commun 2011, 408:447-453.
30. Guerrero E., Gavilanes F., Peterson D.L. Model for the protein arrangement in HBsAg particles based on physical and chemical studies. Viral Hepatitis and Liver Disease 1988, 606-613. Alan R Liss Inc., New York, NY. A.J. Zuckerman (Ed.).
31. Shi L., Caulfield M.J., Chern R.T., Wilson R.A., Sanyal G., Volkin D.B. Pharmaceutical and immunological evaluation of a single-shot hepatitis B vaccine formulated with PLGA microspheres. J Pharm Sci 2002, 91:1019-1035.
32. Stone T.W., Darlington L.G. Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov 2002, 1:609-620.
33. Demchenko A.P., Mely Y., Duportail G., Klymchenko A.S. Monitoring biophysical properties of lipid membranes by environment-sensitive fluorescent probes. Biophys J 2009, 96:3461-3470.
34. Klymchenko A.S., Mely Y., Demchenko A.P., Duportail G. Simultaneous probing of hydration and polarity of lipid bilayers with 3-hydroxyflavone fluorescent dyes. Biochim Biophys Acta 2004, 1665:6-19.